iBio (IBIO) Competitors $0.79 +0.02 (+2.93%) Closing price 04:00 PM EasternExtended Trading$0.80 +0.01 (+1.13%) As of 07:09 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOwnershipSEC FilingsTrendsBuy This Stock IBIO vs. PRLD, ATNM, CELU, STTK, HOWL, RENB, ICCC, DTIL, FBRX, and ARTVShould you be buying iBio stock or one of its competitors? The main competitors of iBio include Prelude Therapeutics (PRLD), Actinium Pharmaceuticals (ATNM), Celularity (CELU), Shattuck Labs (STTK), Werewolf Therapeutics (HOWL), Renovaro (RENB), ImmuCell (ICCC), Precision BioSciences (DTIL), Forte Biosciences (FBRX), and Artiva Biotherapeutics (ARTV). These companies are all part of the "pharmaceutical products" industry. iBio vs. Prelude Therapeutics Actinium Pharmaceuticals Celularity Shattuck Labs Werewolf Therapeutics Renovaro ImmuCell Precision BioSciences Forte Biosciences Artiva Biotherapeutics Prelude Therapeutics (NASDAQ:PRLD) and iBio (NYSE:IBIO) are both small-cap medical companies, but which is the better investment? We will contrast the two companies based on the strength of their community ranking, profitability, institutional ownership, analyst recommendations, risk, valuation, earnings, dividends and media sentiment. Is PRLD or IBIO more profitable? Prelude Therapeutics' return on equity of -66.89% beat iBio's return on equity.Company Net Margins Return on Equity Return on Assets Prelude TherapeuticsN/A -66.89% -55.59% iBio N/A -73.15%-45.51% Does the media prefer PRLD or IBIO? In the previous week, Prelude Therapeutics' average media sentiment score of 0.15 beat iBio's score of 0.00 indicating that Prelude Therapeutics is being referred to more favorably in the media. Company Overall Sentiment Prelude Therapeutics Neutral iBio Neutral Which has preferable earnings & valuation, PRLD or IBIO? iBio has lower revenue, but higher earnings than Prelude Therapeutics. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioPrelude Therapeutics$7M7.37-$121.83M-$1.69-0.54iBio$375K33.94-$24.91MN/AN/A Do institutionals and insiders believe in PRLD or IBIO? 79.7% of Prelude Therapeutics shares are owned by institutional investors. Comparatively, 7.9% of iBio shares are owned by institutional investors. 63.9% of Prelude Therapeutics shares are owned by company insiders. Comparatively, 0.6% of iBio shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth. Do analysts rate PRLD or IBIO? Prelude Therapeutics currently has a consensus target price of $4.00, indicating a potential upside of 337.59%. iBio has a consensus target price of $4.30, indicating a potential upside of 458.15%. Given iBio's stronger consensus rating and higher probable upside, analysts clearly believe iBio is more favorable than Prelude Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Prelude Therapeutics 1 Sell rating(s) 0 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 2.33iBio 0 Sell rating(s) 0 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 3.00 Which has more volatility and risk, PRLD or IBIO? Prelude Therapeutics has a beta of 1.3, suggesting that its share price is 30% more volatile than the S&P 500. Comparatively, iBio has a beta of 1.19, suggesting that its share price is 19% more volatile than the S&P 500. Does the MarketBeat Community prefer PRLD or IBIO? Prelude Therapeutics received 29 more outperform votes than iBio when rated by MarketBeat users. Likewise, 51.56% of users gave Prelude Therapeutics an outperform vote while only 44.44% of users gave iBio an outperform vote. CompanyUnderperformOutperformPrelude TherapeuticsOutperform Votes3351.56% Underperform Votes3148.44% iBioOutperform Votes444.44% Underperform Votes555.56% SummaryPrelude Therapeutics beats iBio on 8 of the 13 factors compared between the two stocks. Get iBio News Delivered to You Automatically Sign up to receive the latest news and ratings for IBIO and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart IBIO vs. The Competition Export to ExcelMetriciBioPharmaceutical IndustryMedical SectorNYSE ExchangeMarket Cap$12.73M$6.53B$5.38B$19.42BDividend YieldN/A2.64%5.21%3.83%P/E RatioN/A8.9226.8034.23Price / Sales33.94252.24389.7034.85Price / CashN/A65.8538.2517.51Price / Book0.556.466.804.69Net Income-$24.91M$143.98M$3.23B$1.02B7 Day Performance5.82%2.03%1.52%-1.74%1 Month Performance10.06%4.11%10.04%7.46%1 Year Performance-65.45%-2.87%16.73%3.96% iBio Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)IBIOiBio1.1748 of 5 stars$0.79+2.9%$4.30+442.2%-67.1%$13.10M$375,000.000.00100PRLDPrelude Therapeutics3.0402 of 5 stars$0.92+4.6%$4.00+333.0%-77.7%$52.15M$7M-0.52120ATNMActinium Pharmaceuticals1.2111 of 5 stars$1.79+7.2%$4.00+123.5%N/A$52.10M$81,000.00-1.2930Trending NewsCELUCelularity0.0998 of 5 stars$2.17+6.4%N/A-34.8%$51.66M$54.22M-0.82220News CoverageAnalyst DowngradeGap DownSTTKShattuck Labs2.5752 of 5 stars$1.05-4.5%$7.50+614.3%-86.1%$50.29M$4.61M-0.69100Gap UpHOWLWerewolf Therapeutics3.2766 of 5 stars$1.12+0.9%$8.33+644.0%-78.4%$50.26M$1.14M-0.7340RENBRenovaro0.8298 of 5 stars$0.32-1.9%N/A-69.9%$50.12MN/A-0.3420News CoverageGap UpICCCImmuCell0.1776 of 5 stars$5.48+4.0%N/A+29.0%$49.52M$26.49M-10.9670Gap UpDTILPrecision BioSciences3.4422 of 5 stars$4.69-0.4%$47.00+902.1%-64.4%$49.48M$68.70M78.18200Earnings ReportAnalyst ForecastFBRXForte Biosciences2.6387 of 5 stars$7.50-4.5%$32.50+333.3%+30,134.7%$49.37MN/A-0.465News CoverageEarnings ReportAnalyst DowngradeARTVArtiva Biotherapeutics1.7007 of 5 stars$2.02-0.5%$19.40+860.4%N/A$49.21M$251,000.000.0081 Related Companies and Tools Related Companies PRLD Alternatives ATNM Alternatives CELU Alternatives STTK Alternatives HOWL Alternatives RENB Alternatives ICCC Alternatives DTIL Alternatives FBRX Alternatives ARTV Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NYSE:IBIO) was last updated on 5/22/2025 by MarketBeat.com Staff From Our PartnersWatch This Robotics Demo Before July 23rdJeff Brown, the tech legend who picked shares of Nvidia in 2016 before they jumped by more than 22,000%... ...Brownstone Research | SponsoredWhite House to reset Social Security?Elon Musk's parting DOGE gift looks set to shock America... A single announcement by July 22nd could soon b...Altimetry | SponsoredTrump Predicts Dollar DownfallREAD THIS VERY CAREFULLY: If you have $100,000 or more saved for retirement, this may make you VERY angry... ...Augusta Precious Metals | SponsoredThe Secret Map of America, Declassified…Locked inside a Maryland man’s private safe is a map. But not just any map, mind you… This map shows a “...Banyan Hill Publishing | SponsoredThe Robotics Revolution has arrived … and one $7 stock could take off as a result.Robots aren't coming to America in 2025. They are already here. Oxford Economics says, "The Robotics Rev...Weiss Ratings | SponsoredElon’s backup plan for AIElon knows the future isn’t about smarter AI — it’s about powering it. And this new technology is quietly b...True Market Insiders | SponsoredJuly 2025 Rule Change to Impact Retirement InvestorsThere's a massive change from a new rule going into effect this July. And it's one the Big Banks are alread...Premier Gold Co | SponsoredCollect $7k per month from Tesla’s SECRET dividendI just uncovered a strategy that could pay out up to $7,013 every month—without needing a traditional dividend...Investors Alley | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding iBio, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share iBio With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
